Appendix 4D and Half Year Report
Filed with ASX · · 26 pages · English
Brief explanation of any of the figures reported above necessary to enable the figures to be understood: Paradigm Biopharmaceuticals Ltd. is a late-stage clinical development company without commercial revenue, Paradigm expects to continue incurring operating losses as it advances iPPS through pivotal clinical and regulatory milestones. Paradigm recorded a loss before tax of A$23,244,389 for the h
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Drawdown of Tranche 3 under the Convertible Note Facility
- Published Canine Study Strengthens iPPS Phase 3 Rationale
- Oral OA Animal Therapy Progresses via AVet Deal
- December 2025 Quarterly Activities Report & Appendix 4C
- iPPS Phase 2 Biomarker Results Published in Leading Journal
Later from Paradigm Biopharmaceuticals
- Paradigm Achieves 50% Patient Dosing in Phase 3
- Upsized $14M Placement Extends Runway Post IA
- March 2026 Quarterly Activities Report & Appendix 4C
- DSMB 20% Review Supports Phase 3, Moldova Activated
- Results of Share Purchase Plan
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals